RT Journal Article SR Electronic T1 Tadalafil for benign prostatic hyperplasia JF Drug and Therapeutics Bulletin JO Drug Ther Bull FD BMJ Publishing Group Ltd SP 93 OP 96 DO 10.1136/dtb.2013.8.0199 VO 51 IS 8 YR 2013 UL http://dtb.bmj.com/content/51/8/93.abstract AB Tadalafil is a phosphodiesterase type-5 (PDE5) inhibitor licensed for the treatment of erectile dysfunction (ED) in adult males (Cialis—Lilly) and for the management of pulmonary arterial hypertension (Adcirca—Lilly).1 The 5mg tablet was licensed in November 2012 for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH) in adult males (Cialis 5mg—Lilly).2 In this article, we consider the evidence for tadalafil and how its use fits with current management strategies for BPH.